Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | nitric oxide synthase 2, inducible | Starlite/ChEMBL | References |
Homo sapiens | solute carrier family 6 (neurotransmitter transporter), member 2 | Starlite/ChEMBL | References |
Homo sapiens | nitric oxide synthase 1 (neuronal) | Starlite/ChEMBL | References |
Homo sapiens | nitric oxide synthase 3 (endothelial cell) | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | Sodium:neurotransmitter symporter family protein | solute carrier family 6 (neurotransmitter transporter), member 2 | 617 aa | 638 aa | 32.5 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | 0.0109 | 1 | 1 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.0091 | 0.7578 | 1 |
Plasmodium vivax | flavodoxin domain containing protein | 0.0081 | 0.6183 | 0.8159 |
Giardia lamblia | Hypothetical protein | 0.0081 | 0.6183 | 0.5 |
Leishmania major | p450 reductase, putative | 0.0091 | 0.7578 | 1 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.0046 | 0.1488 | 0.0108 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.0091 | 0.7578 | 0.6596 |
Leishmania major | cytochrome P450 reductase, putative | 0.0081 | 0.6183 | 0.8159 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0056 | 0.2883 | 0.173 |
Echinococcus granulosus | serotonin transporter | 0.0109 | 1 | 1 |
Onchocerca volvulus | 0.0109 | 1 | 0.5 | |
Loa Loa (eye worm) | norepinephrine transporter | 0.0109 | 1 | 1 |
Schistosoma mansoni | norepinephrine/norepinephrine transporter | 0.0109 | 1 | 1 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.0091 | 0.7578 | 1 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.0091 | 0.7578 | 1 |
Treponema pallidum | sodium- and chloride- dependent transporter | 0.0109 | 1 | 1 |
Schistosoma mansoni | sodium/chloride dependent transporter | 0.0109 | 1 | 1 |
Brugia malayi | FAD binding domain containing protein | 0.0091 | 0.7578 | 0.7578 |
Loa Loa (eye worm) | hypothetical protein | 0.0109 | 1 | 1 |
Echinococcus multilocularis | serotonin transporter | 0.0109 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0091 | 0.7578 | 1 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.0091 | 0.7578 | 0.6596 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0091 | 0.7578 | 1 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.0091 | 0.7578 | 0.5 |
Trypanosoma cruzi | p450 reductase, putative | 0.0091 | 0.7578 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0035 | 0 | 0.5 |
Loa Loa (eye worm) | serotonin transporter b | 0.0109 | 1 | 1 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.0081 | 0.6183 | 0.5 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0091 | 0.7578 | 1 |
Brugia malayi | FAD binding domain containing protein | 0.0056 | 0.2883 | 0.2883 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0035 | 0 | 0.5 |
Loa Loa (eye worm) | solute carrier family 6 member 4 | 0.0109 | 1 | 1 |
Brugia malayi | flavodoxin family protein | 0.0091 | 0.7578 | 0.7578 |
Trichomonas vaginalis | sulfite reductase, putative | 0.0091 | 0.7578 | 1 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.0091 | 0.7578 | 1 |
Schistosoma mansoni | cytochrome P450 reductase | 0.0091 | 0.7578 | 0.7185 |
Trichomonas vaginalis | NADPH fad oxidoreductase, putative | 0.0081 | 0.6183 | 0.8159 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.0091 | 0.7578 | 0.6596 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.0091 | 0.7578 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0035 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0091 | 0.7578 | 0.7578 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0091 | 0.7578 | 1 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0045 | 0.1395 | 0.5 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.0091 | 0.7578 | 0.6596 |
Chlamydia trachomatis | sulfite reductase | 0.0056 | 0.2883 | 0.5 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0091 | 0.7578 | 0.7578 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0035 | 0 | 0.5 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0035 | 0 | 0.5 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0056 | 0.2883 | 0.2883 |
Loa Loa (eye worm) | hypothetical protein | 0.0109 | 1 | 1 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.0091 | 0.7578 | 1 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0045 | 0.1395 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 0.3 uM | Inhibition of human nNOS expressed in baculovirus-infected insect sf9 cells assessed as conversion of [3H]-L-arginine to [3H]-L-citrulline preincubated for 15 mins with compound measured after 45 mins by scintillation counting | ChEMBL. | 22420844 |
IC50 (binding) | = 0.88 uM | Displacement of [3H]nisoxetine from human NET expressed in CHO cells after 120 mins by scintillation counting | ChEMBL. | 22420844 |
IC50 (binding) | = 7.76 uM | Inhibition of human eNOS expressed in baculovirus-infected insect sf9 cells assessed as conversion of [3H]-L-arginine to [3H]-L-citrulline preincubated for 15 mins with compound measured after 45 mins by scintillation counting | ChEMBL. | 22420844 |
IC50 (binding) | = 14.5 uM | Inhibition of human iNOS expressed in baculovirus-infected insect sf9 cells assessed as conversion of [3H]-L-arginine to [3H]-L-citrulline preincubated for 15 mins with compound measured after 45 mins by scintillation counting | ChEMBL. | 22420844 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.